Medicus Pharma Ltd (MDCX) Price & Analysis

Compare

183 Followers

MDCX Stock Chart & Stats

$1.46

-$0.29(-9.70%)

At close: Jan 08 4:00 PM EST

$1.46

-$0.29(-9.70%)

Day’s Range― - ―

52-Week Range$1.07 - $8.94

Previous CloseN/A

Volume5.92K

Average Volume (3M)264.29K

Market Cap

$28.88M

Enterprise Value$18.51M

Total Cash (Recent Filing)$8.66M

Total Debt (Recent Filing)$236.26K

Price to Earnings (P/E)―

Beta1.34

Next Earnings

Mar 30, 2026

EPS Estimate

-0.15

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.12

Shares Outstanding25,114,143

10 Day Avg. Volume348,975

30 Day Avg. Volume264,290

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)7.46

Price to Sales (P/S)0.00

P/FCF Ratio-2.28

Enterprise Value/Market Cap0.64

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-0.65

Forecast

1Y Price Target

$12.00

Price Target Upside721.92% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.78

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Collaborations And Real-world DataA one-year milestone-based collaboration with Reliant AI capped at $200,000 and an Expanded Access arrangement with the Gorlin Syndrome Alliance provide capital-efficient development support and opportunities to generate supportive real-world data and visibility ahead of key catalysts.

Regulatory Pathway And IncentivesSubmission for a Commissioner's National Priority Review voucher and FDA alignment on a 505(b)(2) pathway, including bioequivalence study guidance and device improvement recommendations, supports a clearer regulatory path for SkinJect.

Royalty And Intellectual PropertyA license amendment materially reduced the royalty burden while preserving global rights and intellectual property, making the asset more attractive for future licensing or partnering.

Bears Say

Commercial Uptake RiskIf durability issues are not resolved, commercial uptake could be limited despite any safety or dosing advantages, reducing the overall market potential for the therapy.

Dose Optimization And Trial ComplexitySuboptimal durability at the tested dose may necessitate dose adjustments or additional trials, increasing development complexity and potential program costs.

Durability Of ResponsePrior mid-stage data showed a strong initial response but durability was suboptimal at the evaluated dose, creating a development risk that must be addressed to demonstrate lasting clinical benefit.

Medicus Pharma Ltd News

Medicus announces amendment to LifeArc license improving Teverelix profile

Medicus Pharma (MDCX) announces that its subsidiary, Antev, has entered into Amendment No. 3 to its license agreement...

15d ago

MDCX

Medicus Pharma announces clinical data on Teverelix

Medicus Pharma (MDCX) announces that detailed clinical data on Teverelix, its long-acting gonadotropin-releasing hormone antagonist, have been accepted...

25d ago

MDCX

Medicus Pharma Lowers Teverelix Royalty Burden in Amended LifeArc License

An update from Medicus Pharma Ltd ( ($MDCX) ) is now available. Medicus Pharma’s subsidiary Antev has amended...

15d ago

MDCX

Medicus Pharma Highlights Positive Teverelix Phase 1 Data and Near-Term SkinJect Milestones

Medicus Pharma Ltd ( ($MDCX) ) has shared an announcement. Medicus Pharma reported Phase 1 data showing that...

25d ago

MDCX

Medicus Pharma Ramps Up Partnering Push as Phase 2 SkinJect Data Nears

Medicus Pharma Ltd ( ($MDCX) ) just unveiled an update. Medicus Pharma will present at Biotech Showcase 2026...

1M ago

MDCX

Medicus Pharma Launches At-the-Market Equity Offering Program

The latest update is out from Medicus Pharma Ltd ( ($MDCX) ). On December 29, 2025, Medicus Pharma...

1M ago

MDCX

Medicus Pharma Taps Reliant AI for Data-Driven Teverelix Clinical Development

Medicus Pharma Ltd ( ($MDCX) ) has shared an update. Medicus Pharma Ltd. has signed a non-binding letter...

2M ago

MDCX

Medicus Pharma enters non-binding LOI with Reliant AI

Medicus Pharma (MDCX) entered into non-binding letter of intent with Reliant AI to collaborate on the development of...

2M ago

MDCX

Medicus Pharma Completes Patient Enrollment for Phase 2 BCC Treatment Study

Medicus Pharma Ltd ( ($MDCX) ) just unveiled an update. Medicus Pharma Ltd. has completed enrollment of 90...

2M ago

MDCX

Medicus Pharma completes enrollment of 90 patients for Phase 2 study

Medicus Pharma (MDCX) announced that its Phase 2 clinical study evaluating safety and efficacy of Doxorubicin Microneedle Array...

2M ago

MDCX

Medicus Pharma’s Warrant Inducement Agreement Announced

Medicus Pharma Ltd ( ($MDCX) ) has issued an announcement. On December 5, 2025, Medicus Pharma Ltd. entered...

2M ago

MDCX

Medicus Pharma Ltd. Strengthens Leadership and Expands Clinical Trials

Medicus Pharma Ltd ( ($MDCX) ) has provided an announcement. Medicus Pharma Ltd. has appointed Carolyn Bonner as...

2M ago

MDCX

Medicus Pharma appoints Carolyn Bonner as CFO

Medicus Pharma (MDCX) announced that Carolyn Bonner, currently President of the Company, has also been appointed CFO, effective...

2M ago

MDCX

Medicus Pharma explores novel treatment innovations for prostate, skin cancers

The company said, “November is Men’s Health Awareness Month, a time to spotlight the latest medical breakthroughs that...

2M ago

MDCX

MDCX FAQ

What was Medicus Pharma Ltd’s price range in the past 12 months?

Medicus Pharma Ltd lowest stock price was $1.07 and its highest was $8.94 in the past 12 months.

What is Medicus Pharma Ltd’s market cap?

Medicus Pharma Ltd’s market cap is $28.88M.

When is Medicus Pharma Ltd’s upcoming earnings report date?

Medicus Pharma Ltd’s upcoming earnings report date is Mar 30, 2026 which is in 52 days.

How were Medicus Pharma Ltd’s earnings last quarter?

Medicus Pharma Ltd released its earnings results on Nov 21, 2025. The company reported -$1.12 earnings per share for the quarter, missing the consensus estimate of -$0.945 by -$0.175.

Is Medicus Pharma Ltd overvalued?

According to Wall Street analysts Medicus Pharma Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Medicus Pharma Ltd pay dividends?

Medicus Pharma Ltd does not currently pay dividends.

What is Medicus Pharma Ltd’s EPS estimate?

Medicus Pharma Ltd’s EPS estimate is -0.15.

How many shares outstanding does Medicus Pharma Ltd have?

Medicus Pharma Ltd has 25,114,143 shares outstanding.

What happened to Medicus Pharma Ltd’s price movement after its last earnings report?

Medicus Pharma Ltd reported an EPS of -$1.12 in its last earnings report, missing expectations of -$0.945. Following the earnings report the stock price went up 4.412%.

Which hedge fund is a major shareholder of Medicus Pharma Ltd?

Currently, no hedge funds are holding shares in MDCX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medicus Pharma Ltd

Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets, with an emphasis on non-invasive treatments for skin cancer.

Medicus Pharma Ltd (MDCX) Earnings & Revenues

Historic Earnings Reports

MDCX Stock 12 Month Forecast

Average Price Target

$12.00

▲(721.92% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.53,2.3353846153846156,3.140769230769231,3.9461538461538463,4.751538461538462,5.556923076923078,6.362307692307693,7.167692307692309,7.973076923076924,8.778461538461539,9.583846153846155,10.38923076923077,11.194615384615386,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.53,2.3353846153846156,3.140769230769231,3.9461538461538463,4.751538461538462,5.556923076923078,6.362307692307693,7.167692307692309,7.973076923076924,8.778461538461539,9.583846153846155,10.38923076923077,11.194615384615386,{"y":12,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.53,2.3353846153846156,3.140769230769231,3.9461538461538463,4.751538461538462,5.556923076923078,6.362307692307693,7.167692307692309,7.973076923076924,8.778461538461539,9.583846153846155,10.38923076923077,11.194615384615386,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.56,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.46,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.46,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.99,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.32,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.95,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.24,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.44,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.98,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.53,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >